Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease

Brain

Volumn 138, Issue 10, 2015, Pages 3003-3015

  Niccolini, Flavia ^a,b   Foltynie, Thomas ^c   Reis Marques, Tiago ^a   Muhlert, Nils ^d,e   Tziortzi, Andri C ^f   Searle, Graham E ^f   Natesan, Sridhar ^a   Kapur, Shitij ^a   Rabiner, Eugenii A ^a,f   Gunn, Roger N ^b   Piccini, Paola ^b   Politis, Marios ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

LIDs; motor; Parkinson's disease; PDE10A; PET

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; IMA107; PDE10A PROTEIN, HUMAN; QUINOXALINE DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL GANGLION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLOBUS PALLIDUS; HUMAN; IN VIVO STUDY; MALE; MIDDLE AGED; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; SIGNAL NOISE RATIO; SUBSTANTIA NIGRA; THALAMUS NUCLEUS; UNIFIED PARKINSON DISEASE RATING SCALE; BRAIN; BRAIN MAPPING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMAGE PROCESSING; METABOLISM; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX; STATISTICS;

AGED; BRAIN; BRAIN MAPPING; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR ACTIVITY; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; QUINOXALINES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 84952895163     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv219     Document Type: Article

References (55)

1. Ahmad R, Bourgeois S, Postnov A, Schmidt ME, Bormans G, Van Laere K, et al. PET imaging shows loss of striatal PDE10A in patients with Huntington disease. Neurology 2014; 82: 279-81.
2. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999; 7: 254-66.
3. Barret O, Thomae D, Tavares A, Alagille D, Papin C, Waterhouse R, et al. In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654. J Nucleic Med 2014; 55: 1297-304.
4. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
5. Berman BD, Starr PA, Marks WJ, Jr, Ostrem JL. Induction of bradykinesia with pallidal deep brain stimulation in patients with cranialcervical dystonia. Stereotact Funct Neurosurg 2009; 87: 37-44.
6. Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009; 73: 1670-6.
7. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinsons disease. J Neurol Neurosurg Psychiatry 1997; 62: 133-40.
8. Broussolle E, Dentresangle C, Landais P, Garcia-Larrea L, Pollak P, Croisile B, et al. The relation of putamen and caudate nucleus 18FDopa uptake to motor and cognitive performances in Parkinsons disease. J Neurol Sci 1999; 166: 141-51.
9. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004; 23: 724-38.
10. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006; 54: 1205-13.
11. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969; 280: 337-45.
12. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9.
13. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, et al. Biochemical variations in the synaptic levels of dopamine precede motor fluctuations in Parkinsons disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49: 298-303.
14. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human Brain. Neuron 2002; 33: 341-55.
15. Fredholm BB, Ba?ttig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
16. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RS. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 2: 189-210.
17. Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999; 266: 1118-27.
18. Giorgi M, DAngelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 2008; 28: 941-50.
19. Giorgi M, Melchiorri G, Nuccetelli V, DAngelo V, Martorana A, Sorge R, et al. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology. Neurobiol Dis 2011; 43: 293-303.
20. Girault JA. Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol 2012; 970: 407-29.
21. Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: the DARPP- 32/protein phosphatase-1 cascade. Neuron 1999; 23: 435-47.
22. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-87.
23. Herve D, Le Moine C, Corvol JC, Belluscio L, Ledent C, Fienberg AA, et al. Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 2001; 21: 4390-99.
24. Hossain MA, Weiner N. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinsons disease. J Pharmacol Exp Ther 1993; 267: 1105-11.
25. Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, et al. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol 2014; 71: 758-66.
26. Jellinger KA. Pathology of Parkinsons disease. Mol Chem Neuropathol 1991; 3: 153-97.
27. Kelly MP, Adamowicz W, Bove S, Hartman AJ, Mariga A, Pathak G, et al. Select 3,5-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. Cell Signal 2014; 26: 383-97.
28. Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinsons disease. Brain 1998; 121: 451-7.
29. Lees AJ, Shaw KM, Stern GM. Off period dystonia and on period choreoathetosis in levodopatreated patients with Parkinsons disease. Lancet 1977; 2: 1034.
30. Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 2013; 80: 1850-5.
31. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinsons disease progression. Neurology 2001; 57: 2089-94.
32. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM. Correction of head movement on PET studies: comparison of methods. J Nucleic Med 2006; 47: 1936-44.
33. Nishi A, Kuroiwa M, Miller DB, OCallaghan JP, Bateup HS, Shuto T, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 2008; 28: 10460-71.
34. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinsons disease: correlations with the three main symptoms. J Neurol Sci 1996; 136: 169-73.
35. Peterson DS, Pickett KA, Duncan RP, Perlmutter JS, Earhart GM. Brain activity during complex imagined gait tasks in Parkinson disease. Clin Neurophysiol 2014; 125: 995-1005.
36. Picconi B, Bagetta V, Ghiglieri V, Paille V, Greengard P, Fisone G, et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011; 134: 375-87.
37. Picconi B, Centonze D, Haakansson K, Bernardi G, Barone I, Lindgren HS, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-6.
38. Picconi B, Paille?V, Ghiglieri V, Bagetta V, Di Filippo M, Pendolino V, et al. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008; 229: 327-35.
39. Plisson C, Salinas C, Weinzimmer D, Labaree D, Lin SF, Ding YS, et al. Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucleic Med Biol 2011; 38: 875-84.
40. Plisson C, Weinzimmer D, Jakobsen S, Natesan S, Salinas C, Lin SF, et al. Phosphodiesterase 10A PET radioligand development program: from pig to human. J Nucleic Med 2014; 55: 595-601.
41. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al. P, Staging of serotonergic dysfunction in Parkinsons disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010; 40: 216-21.
42. Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinsons disease patients. J Clin Invest 2014; 124: 1340-9.
43. Potter-Nerger M, Volkmann J. Deep brain stimulation for gait and postural symptoms in Parkinsons disease. Mov Disord 2013 28 1609-15
44. Prodoehl J, Yu H, Little DM, Abraham I, Vaillancourt DE. Region of interest template for the human basal ganglia: comparing EPI and standardized space approaches. Neuroimage 2008; 39: 956-65.
45. Rasmussen H. Cell communication, calcium ion, and cyclic adenosine monophosphate. Science 1970; 170: 404-12.
46. Russell DS, Barret O, Jennings DL, Friedman JH, Tamagnan GD, Thomae D, et al. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early huntington disease. JAMA Neurol 2014; 71: 1520-8.
47. Sancesario G, Morrone LA, DAngelo V, Castelli V, Ferrazzoli D, Sica F, et al. Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism? Neurochem Int 2014; 79: 44-56.
48. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003; 985: 113-126.
49. Shine JM, Matar E, Ward PB, Bolitho SJ, Gilat M, Pearson M, et al. Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinsons disease. Brain 2013; 136: 1204-15.
50. Stoof JC, Kebabian JW. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981; 294: 366-8.
51. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24: 25-35.
52. Sudhyadhom A, Haq IU, Foote KD, Okun MS, Bova FJ. A high resolution and high contrast MRI for differentiation of subcortical structures for DBS targeting: The Fast Gray Matter Acquisition T1 Inversion Recovery (FGATIR), Neuroimage 2009; 47: T44-52.
53. Tanner M, Gambarota G, Kober T, Krueger G, Erritzoe D, Marques JP, et al. Fluid and white matter suppression with the MP2RAGE sequence. J Magn Reson Imaging 2013; 35: 1063-70.
54. Tenn CC, Niles LP. Sensitization of G protein-coupled benzodiazepine receptors in the striatum of 6-hydroxydopamine-lesioned rats. J Neurochem 1997; 69: 1920-6.
55. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, et al. Imaging dopamine receptors in humans with [11C]-( + )-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011; 54: 264-77.